Stephen Davis and Barry Quart, two veterans of the life science industry, have been named to the board of directors at Trimeris.
The drug development company is shuffling its board following the requested departures of its chief executive officer and chief financial officer in March.
David is chief operating officer of Neurogen. Quart is CEO of Ardea Biosciences.
“These two new directors bring many years of experience in the biotechnology industry and expertise in product development, commercialization and corporate finance, which will greatly assist Trimeris in achieving its strategic and financial objectives,” said Larry Hill, interim president and COO of Trimeris.
Trimeris (NASDAQ: TRMS) and drug development partner Roche recently ended their joint efforts at developing a potential HIV treatment called TRI-1144. Trimeris is developing TRI-1144 on its own. Roche and Trimeris continue to work together on the HIV drug Fuzeon.
Former CEO and company co-founder Dani Bolognesi is leaving the board along with Richard Crout, Jeffrey Lipton and Gary Cook. The retirements of Lipton and Cook were disclosed Friday.
